4.8 Review

PALB2/FANCN: Recombining Cancer and Fanconi Anemia

Journal

CANCER RESEARCH
Volume 70, Issue 19, Pages 7353-7359

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-10-1012

Keywords

-

Categories

Funding

  1. Susan G. Komen Foundation
  2. Jewish General Hospital Weekend to End Breast Cancer
  3. Quebec Ministry of Economic Development, Innovation and Export Trade
  4. National Cancer Institute [R01CA138804]
  5. American Cancer Society [RSG-TBG-119822]
  6. Cancer Institute of New Jersey
  7. NATIONAL CANCER INSTITUTE [R01CA138804] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Partner and localizer of BRCA2 (PALB2) was originally identified as a BRCA2-interacting protein that is crucial for key BRCA2 genome caretaker functions. It subsequently became clear that PALB2 was another Fanconi anemia (FA) gene (FANCN), and that monoallelic PALB2 mutations are associated with increased risk of breast and pancreatic cancer. Mutations in PALB2 have been identified in breast cancer families worldwide, and recent studies have shown that PALB2 also interacts with BRCA1. Here, we summarize the molecular functions and clinical phenotypes of this key DNA repair pathway component and discuss how its discovery has advanced our knowledge of both FA and adult cancer predisposition. Cancer Res; 70(19); 7353-9. (C) 2010 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available